Fort Lauderdale, Florida, August 14, 2018 – Jabez Pharma has entered into a multi-product co-development agreement with a leading pharmaceutical company in the generic and 505(b)(2) space.  Under the terms of this agreement, Jabez will acquire an ownership interest in a pipeline of specialty generics, 505(b)(2) and animal health products, which are currently under development.  The products in the most advanced stages of development will be filed with the FDA in the first half of 2019.